Sentiment-Signal
14,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 14.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 11.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 10.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 16.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ation Table in the Prospectus. In accordance with Item 5.02(f), below is a revised Summary Compensation Table, which inc |
Stammdaten
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Unternehmen & Branche
| Name | CG Oncology, Inc. |
|---|---|
| Ticker | CGON |
| CIK | 0001991792 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,55 Mrd. USD |
| Beta | 0,71 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -160,995,000 | -2.08 | 791,592,000 | 752,602,000 | |
| 2025-09-30 | 10-Q | -43,808,000 | -0.57 | 729,913,000 | 687,643,000 | |
| 2025-06-30 | 10-Q | -41,426,000 | -0.54 | 701,445,000 | 670,358,000 | |
| 2025-03-31 | 10-Q | -34,452,000 | -0.45 | 728,181,000 | 704,758,000 | |
| 2024-12-31 | 10-K | -88,039,000 | -1.41 | 754,797,000 | 733,377,000 | |
| 2024-09-30 | 10-Q | -20,405,000 | -0.30 | 552,471,000 | 536,770,000 | |
| 2024-06-30 | 10-Q | -18,902,000 | -0.28 | 564,330,000 | 552,359,000 | |
| 2024-03-31 | 10-Q | -16,934,000 | -0.36 | 579,108,000 | 568,938,000 | |
| 2023-12-31 | 10-K | -48,607,000 | -15.65 | 199,301,000 | -123,100,000 | |
| 2023-09-30 | 10-Q | -11,768,000 | -4.00 | -107,584,000 | ||
| 2023-06-30 | 10-Q | -11,613,000 | -3.93 | -97,388,000 | ||
| 2023-03-31 | 10-Q | -8,671,000 | -3.22 | -86,117,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-09-03 | Song Hong Fang | Director | Open Market Sale | -100 | 28.96 | -2,896.00 | -0,5% | |
| 2025-09-03 | Song Hong Fang | Director | Open Market Sale | -100 | 28.99 | -2,899.00 | -0,5% | |
| 2025-09-03 | Song Hong Fang | Director | Open Market Sale | -30,105 | 28.24 | -850,165.20 | -151,4% | |
| 2025-09-03 | Song Hong Fang | Director | Open Market Sale | -69,695 | 27.60 | -1,923,582.00 | -342,6% | |
| 2025-09-03 | POST LEONARD E | Director | Open Market Sale | -1,000 | 28.00 | -28,000.00 | -5,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.